the Serum Metabolite Based PrecogColo Dx Test for Advanced Colorectal Neoplasia Screening

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-30

Study Completion Date

2024-02-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to Evaluate the diagnostic sensitivity of the serum metabolite based PrecogColo Dx test for advanced colorectal neoplasia Screening, including advanced adenoma and colorectal cancer. There are two steps in this study. Firstly, the diagnostic model is established based on tumor-specific and gut-microbiome related serum metabolites. Secondly, the sensitivity, specificity and accuracy of the diagnostic model is evaluated in detecting advanced adenoma and colorectal cancer stages in an independent multi-centered cohort.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Stool DNA Test for Detection of Advanced Colorectal Neoplasia in Asymptomatic Chinese Community Population

NCT04786704

Colorectal Cancer Colorectal Neoplasm Advanced Adenoma +2 more

COMPLETED

A Prospective Cohort Study on Colorectal Cancer Screening in Community Population

NCT05485077

Colorectal Cancer

RECRUITING

Serial Gut Microbiome and Bacterial Gene Markers Changes After Endoscopic Resection of Colorectal Advanced Neoplasia

NCT05381792

Colorectal Cancer Colorectal Neoplasms Colorectal Adenoma

RECRUITING

Colorectal Cancer Screening Using Stool DNA-based SDC2 and SFRP2 Methylation Test in China

NCT04515082

Colorectal Neoplasm Colorectal Cancer Adenomatous Polyps +3 more

UNKNOWN

A Study on a Blood-based Dual-target Test for CRC Detection

NCT05508503

Colorectal Cancer Colorectal Adenoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects aged \>45 at average risk for development of CRC will be enrolled. Subjects will complete the PrecogColo Dx test, followed by completion of a screening colonoscopy. . Results from PrecogColo Dx test were compared to the results of an optical colonoscopic examination, and histopathological diagnosis of all significant lesions discovered during the colonoscopy, in order to determine the sensitivity for CRC and advanced adenoma, respectively, as well as determining specificity of non-advanced neoplasia individuals. Histopathological results from biopsied tissue or excised lesions were categorized based on the most clinically significant lesion present by a central pathologist.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Adenoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

negative

normal:no findings on colonoscopy hyperplastic polyps: inflammatory or hyperplastic polyps low-risk adenoma:1 or 2 adenoma(s), ≤10 mm in size, non-advanced

PrecogColo Dx test

Intervention Type DIAGNOSTIC_TEST

the serum metabolite based PrecogColo Dx test for advanced colorectal neoplasia Screening, including advanced adenoma and colorectal cancer

Positive

advanced adenoma Advance adenoma, including the following subcategories:

* Adenoma with carcinoma in situ/high grade dysplasia, any size
* Adenoma, villous growth pattern (\>25%), any size
* Adenoma \> 1.0 cm in size
* Serrated lesion, \> 1.0 cm in size early stage CRC: CRC stage I advanced stage CRC: CRC stage II-IV

PrecogColo Dx test

Intervention Type DIAGNOSTIC_TEST

the serum metabolite based PrecogColo Dx test for advanced colorectal neoplasia Screening, including advanced adenoma and colorectal cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PrecogColo Dx test

the serum metabolite based PrecogColo Dx test for advanced colorectal neoplasia Screening, including advanced adenoma and colorectal cancer

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is ≥ 45 years of age at the time of enrollment.
2. Subject presents for a screening colonoscopy.
3. Subject has no symptoms or signs that require immediate, or near term, referral for diagnostic or therapeutic colonoscopy.
4. Subject is able and willing to sign informed consent.

Exclusion Criteria

1. Patients received tumor treatment prior to the drawn of blood sample, including surgical resection, neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy and targeted therapy.
2. Patients received antibiotics within 2 weeks.
3. Patients with indications of emergency surgery, including bleeding, obstruction and perforation.
4. Patients who are positive for Human Immunodeficiency Virus (HIV).
5. Patients with abnormal liver and kidney function.
6. Patients with the history of inflammatory bowel disease.
7. Patients who had history of other malignancies.
8. Subject has a diagnosis or medical history of any of the following conditions:

1. Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP and Gardner's syndrome)
2. Hereditary non-polyposis CRC syndrome (also referred to as "HNPCC" or "Lynch Syndrome")

Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

shigang ding, doctor

Role: PRINCIPAL_INVESTIGATOR

Peking University Third Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.